Your Article Summary
Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab
Bristol Myers-Squibb Company, 06/01/09
Bristol-Myers Squibb Company and Medarex, Inc. announced updated survival results from follow-up extensions of three Phase 2 ipilimumab studies of patients with advanced metastatic melanoma. The two-year survival rate ranged from 29.8 to 41.8 percent in patients who received ipilimumab. Results of the survival data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, FL., May – June 2009.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
In vitro Growth Inhibitory Activity and Malaria Risk in a Cohort Study in Mali
Infection and Immunity, 12/02/09
A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09

See Latest Articles